Catalent unveils OneBio Suite for biologics development

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)

Related tags Catalent Biologics BIO International Conference

Catalent is unveiling its OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs.

The company will announce the new suite during the BIO International Convention this week in Philadelphia, PA.

According to Catalent, OneBio was designed to address biologic development challenges by providing customers with a single contract, program manager, and development timeline.

“In OneBio, Catalent offers its partners the improved communications associated with streamlined program management and a single point of contact, reduced timelines brought about through parallel processing, and the increased flexibility of a global network of expertise and resources,”​ a Catalent spokesperson told us.

In early April, Catalent invested $5m​ in a new drug development center of excellence to expand its hot melt extrusion (HME) capabilities for formulation and drug delivery method optimization.

According to the company, the expansion enables Catalent to develop amorphous dispersions and controlled and modified drug delivery, such as controlled release for enhanced bioavailability.

Catalent also last month announced​ that it is installing new equipment to increase its formulation capabilities and capacity to manufacture controlled-release tablets and capsules.

The $40m investment will see the addition of a laser drill for osmotic drug delivery and stick pack dosage manufacturing capabilities at the company’s Winchester, KY-based facility.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more